Beta-L-2'deoxy-nucleosides for the treatment of hepatitis B

Abstract

This invention is directed to a method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof may be administered either alone or in combination with another 2′-deoxy-β-L-erythro-pentofuranonucleoside or in combination with another anti-hepatitis B agent.

We claim:  
     
         1 . A method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula:  
       
         
           
           
               
               
           
         
       
       wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted.  
     
     
         2 . The method of  claim 1 , wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside is β-L-2′-deoxyadenosine or a pharmaceutically acceptable salt or prodrug thereof, of the formula:  
       
         
           
           
               
               
           
         
       
       wherein R is H, mono, di or tri phosphate, acyl, or alkyl, or a stabilized phosphate derivative (to form a stabilized nucleotide prodrug).  
     
     
         3 . The method of  claim 1 , wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside is β-L-2′-deoxycytidine or pharmaceutically acceptable salt or prodrug thereof of the formula:  
       
         
           
           
               
               
           
         
       
       wherein R is H, mono, di or tri phosphate, acyl, or alkyl, or a stabilized phosphate derivative (to form a stabilzied nucleotide prodrug).  
     
     
         4 . The method of  claim 1 , wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside is β-L-2′-deoxyuridine or pharmaceutically acceptable salt or prodrug thereof of the formula:  
       
         
           
           
               
               
           
         
       
       wherein R is H, mono, di or tri phosphate, acyl, or alkyl, or a stabilized phosphate derivative (to form a stabilzied nucleotide prodrug).  
     
     
         5 . The method of  claim 1 , wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside is β-L-2′-deoxyguanosine or pharmaceutically acceptable salt or prodrug thereof of the formula:  
       
         
           
           
               
               
           
         
       
       wherein R is H, mono, di or tri phosphate, acyl, or alkyl, or a stabilized phosphate derivative (to form a stabilized nucleotide prodrug).  
     
     
         6 . The method of  claim 1 , wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside is β-L-2′-deoxyinosine or pharmaceutically acceptable salt or prodrug thereof of the formula:  
       
         
           
           
               
               
           
         
       
       wherein R is H, mono, di or tri phosphate, acyl, or alkyl, or a stabilized phosphate derivative (to form a stabilized nucleotide prodrug).  
     
     
         7 . The method of  claim 1 , wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside is β-L-thymidine or a pharmaceutically acceptable salt or prodrug thereof of the formula:  
       
         
           
           
               
               
           
         
       
       wherein R is H, mono, di or tri phosphate, acyl, or alkyl, or a stabilized phosphate derivative (to form a stabilized nucleotide prodrug).  
     
     
         8 . A method for treating a host infected with hepatitis B comprising administering an effective amount of two or more anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleosides or a pharmaceutically acceptable salt or prodrug thereof in combination or alternation, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleosides have the formula:  
       
         
           
           
               
               
           
         
       
       wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted.  
     
     
         9 . A method for treating a host infected with hepatitis B comprising administering an effective amount of an anti-HBV biologically active 2′-deoxy-β-L-erythro-pentofuranonucleoside or a pharmaceutically acceptable salt or prodrug thereof in combination or alternation with an additional anti-hepatitis B agent, wherein the 2′-deoxy-β-L-erythro-pentofuranonucleoside has the formula:  
       
         
           
           
               
               
           
         
       
       wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted.  
     
     
         10 . The method of  claim 9 , wherein the additional anti-hepatitis B agent is selected from the group consisting of 3TC, FTC, L-FMAU, DAPD, famciclovir, penciclovir, BMS-200475, bis pom PMEA (adefovir, dipivoxil); lobucavir, ganciclovir, arid ribavarin  
     
     
         11 . A compound or pharmaceutically acceptable salt or prodrug thereof of the formula:  
       
         
           
           
               
               
           
         
       
       wherein R is H, mono, di or tri phosphate, acyl, or alkyl, or a stabilized phosphate derivative (to form a stabilized nucleotide prodrug).  
     
     
         12 . A pharmaceutical composition comprising an effective amount of a compound of  claim 11  in combination with a pharmaceutically acceptable carrier.